Literature DB >> 27293068

Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion.

Amalia Sertedaki1, Athina Markou2, Dimitrios Vlachakis3, Sophia Kossida3, Emilie Campanac4, Dax A Hoffman4, Maria De La Luz Sierra5, Paraskevi Xekouki5, Constantine A Stratakis5, Gregory Kaltsas6, George P Piaditis2, George P Chrousos1, Evangelia Charmandari1.   

Abstract

BACKGROUND: Germline mutations of the KCNJ5 gene encoding Kir3·4, a member of the inwardly rectifying K+ channel, have been identified in 'normal' adrenal glands, patients with familial hyperaldosteronism (FH) type III, aldosterone-producing adenomas (APAs) and sporadic cases of primary aldosteronism (PA).
OBJECTIVE: To present two novel KCNJ5 gene mutations in hypertensive patients without PA, but with Adrenocorticotropic hormone (ACTH)-dependent aldosterone hypersecretion. DESIGN AND PATIENTS: Two hypertensive patients without PA, who exhibited enhanced ACTH-dependent response of aldosterone secretion, underwent genetic testing for the presence of the CYP11B1/CYP11B2 chimeric gene and KCNJ5 gene mutations. Genomic DNA was isolated from peripheral white blood cells, and the exons of the entire coding regions of the above genes were amplified and sequenced. Electrophysiological studies were performed to determine the effect of identified mutation(s) on the membrane reversal potentials. Structural biology studies were also carried out.
RESULTS: Two novel germline heterozygous KCNJ5 mutations, p.V259M and p.Y348N, were detected in the two subjects. Electrophysiological studies showed that the Y348N mutation resulted in significantly less negative reversal potentials, suggesting loss of ion selectivity, while the V259M mutation did not affect the Kir3.4 current. In the mutated structural biology model, the N348 mutant resulted in significant loss of the ability for hydrogen bonding, while the M259 mutant was capable of establishing weaker interactions. The CYP11B1/CYP11B2 chimeric gene was not detected.
CONCLUSIONS: These findings expand on the clinical spectrum of phenotypes associated with KCNJ5 mutations and implicate these mutations in the pathogenesis of hypertension associated with increased aldosterone response to ACTH stimulation.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27293068      PMCID: PMC5118167          DOI: 10.1111/cen.13132

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  28 in total

1.  Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

Authors:  Ute I Scholl; Carol Nelson-Williams; Peng Yue; Roger Grekin; Robert J Wyatt; Michael J Dillon; Robert Couch; Lisa K Hammer; Frances L Harley; Anita Farhi; Wen-Hui Wang; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

3.  A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III.

Authors:  Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2008-08       Impact factor: 5.958

4.  Role of calcium and cAMP in the action of adrenocorticotropin on aldosterone secretion.

Authors:  I Kojima; K Kojima; H Rasmussen
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

5.  Glucocorticoid-remediable aldosteronism.

Authors:  Florencia Halperin; Robert G Dluhy
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 6.  Regulation of aldosterone biosynthesis by the Kir3.4 (KCNJ5) potassium channel.

Authors:  Carolina Velarde-Miranda; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

7.  Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms).

Authors:  Paolo Mulatero; Davide Tizzani; Andrea Viola; Chiara Bertello; Silvia Monticone; Giulio Mengozzi; Domenica Schiavone; Tracy Ann Williams; Silvia Einaudi; Antonio La Grotta; Franco Rabbia; Franco Veglio
Journal:  Hypertension       Date:  2011-08-29       Impact factor: 10.190

8.  K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.

Authors:  Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 9.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

Review 10.  Primary aldosteronism: an update on screening, diagnosis and treatment.

Authors:  Gian Paolo Rossi; Achille Cesare Pessina; Anthony M Heagerty
Journal:  J Hypertens       Date:  2008-04       Impact factor: 4.844

View more
  5 in total

Review 1.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

Review 2.  Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Authors:  Xin He; Zubin Modi; Tobias Else
Journal:  Gland Surg       Date:  2020-02

3.  Cushing Syndrome in a Pediatric Patient With a KCNJ5 Variant and Successful Treatment With Low-dose Ketoconazole.

Authors:  Christina Tatsi; Andrea G Maria; Cole Malloy; Lin Lin; Edra London; Nick Settas; Chelsi Flippo; Meg Keil; Fady Hannah-Shmouni; Dax A Hoffman; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 4.  An update on adrenal endocrinology: significant discoveries in the last 10 years and where the field is heading in the next decade.

Authors:  Crystal D C Kamilaris; Constantine A Stratakis
Journal:  Hormones (Athens)       Date:  2018-11-19       Impact factor: 2.885

Review 5.  Unravelling the Genetic Basis of Primary Aldosteronism.

Authors:  Niki Mourtzi; Amalia Sertedaki; Athina Markou; George P Piaditis; Evangelia Charmandari
Journal:  Nutrients       Date:  2021-03-08       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.